舒利迭联合思力华治疗COPD的临床疗效观察

Clinical observation of seretide and spiriva in the treatment of chronic obstructive pulmonary disease

目的探讨舒利迭联合思力华治疗COPD的临床疗效。方法 96例患者随机分为对照组46例和治疗组50例。对照组给予舒利迭500/50μg,2次/d,治疗组在对照组基础上给予思力华18μg,1次/d,治疗3月。统计疗效,于治疗前后分别行CAT评分,测定肺功能FEV1、FEV1/FVC(%)、血气分析、6 min步行距离。结果治疗组治疗的总有效率达96.0%,明显优于对照组(χ2=7.033,P<0.05);经治疗后CAT评分两组患者均有显著下降(P<0.01,P<0.01),治疗组CAT评分明显低于对照组(P<0.05);两组患者肺功能均有改善(P<0.05,P<0.01),治疗组肺功能改善高于对照组(P<0.05);血气指标中PCO2和PaO2治疗组较对照组改善更明显(P<0.05);6 min步行距离治疗组明显增加(P<0.01)。结论舒利迭与思力华联合使用治疗COPD稳定期可明显改善症状、肺功能,疗效显著。

Objective To observe the effect of seretide and spiriva in the treatment of chronic obstructive pulmonary disease （ COPD） . Methods 96 patients were randomly divided into the treatment group with 50 cases and the control group with 46 cases. Both groups were given conventional therapy. The control group was given seretide twice a day, and the treatment group was given seretide twice a day and spiriva once a day. The two groups were treated for 3 months. The score of CAT, FEV1 and FEV1/FVC （%） , PaCO2 , PaO2 and 6-min walk distance of the two groups were detected before and after the treatment. Results The total effective rate of the treatment group was 96%, which was higher than that in the control group （χ2 =7. 033, P〈0. 05）. The score of CAT of the two groups significantly improve after treatment （P〈0. 01）, but the improvement was more pronounced in the treatment group than in the control group （P〈0. 05）. Compared with the control group after treatment, lung function of the treatment group increased significantly （P〈0. 05）, 6-min walk distance increased significantly （P〈0. 01）, and PaCO2 and PaO2 of arterial blood improve significantly （ P〈0. 05 ） . Conclusion Serefide and spiriva can improve clinical symptoms and lung function of patients with COPD obviously.